Get started
Author

Yangmi Lim

Observed institution: ABL Bio (South Korea)
ORCID: 0009-0000-4400-5514
Observed ORCID: 0009-0000-4400-5514
OpenAlex ID: A5102508414
A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
2025 · Geoffrey Ku, Lin Shen, et al. · Clinical Cancer Research · 30
PDF
CLEC12A-directed immunocytokine with target cell–restricted IL-15 activity for treatment of acute myeloid leukemia
2025 · Boris Klimovich, Leonard Anton, et al. · Frontiers in Immunology · 3
Supplementary Figure 2 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
2025 · Geoffrey Ku, Lin Shen, et al. · 1
Supplementary Table 3 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
2025 · Geoffrey Ku, Lin Shen, et al.
Supplementary Table 6 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
2025 · Geoffrey Ku, Lin Shen, et al.
Supplementary Figure 7 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
2025 · Geoffrey Ku, Lin Shen, et al.
Supplementary Table 4 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
2025 · Geoffrey Ku, Lin Shen, et al.
Supplementary Figure 6 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
2025 · Geoffrey Ku, Lin Shen, et al.
Supplementary Table 8 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
2025 · Geoffrey Ku, Lin Shen, et al.
Supplementary Figure 3 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
2025 · Geoffrey Ku, Lin Shen, et al.
Supplementary Figure 5 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
2025 · Geoffrey Ku, Lin Shen, et al.
Supplementary Table 1 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
2025 · Geoffrey Ku, Lin Shen, et al.
Supplementary Table 7 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
2025 · Geoffrey Ku, Lin Shen, et al.
Supplementary Table 5 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
2025 · Geoffrey Ku, Lin Shen, et al.
Supplementary Figure 4 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
2025 · Geoffrey Ku, Lin Shen, et al.
Supplementary Table 2 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
2025 · Geoffrey Ku, Lin Shen, et al.
Data from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
2025 · Geoffrey Ku, Lin Shen, et al.
Supplementary Figure 1 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
2025 · Geoffrey Ku, Lin Shen, et al.
Abstract B016: Updated Safety, Efficacy and Biomarker Analysis from the Phase I Study of Givastomig, a Novel Claudin 18.2/4-1BB Bispecific Antibody, in Claudin 18.2 Positive Advanced Gastroesophageal Carcinoma (GEC)
2025 · Samuel J. Klempner, Lin Shen, et al. · Molecular Cancer Therapeutics
Supplementary method from GC1118, an Anti-EGFR Antibody with a Distinct Binding Epitope and Superior Inhibitory Activity against High-Affinity EGFR Ligands
2023 · Yangmi Lim, Jiho Yoo, et al.
Supplementary table 1 from GC1118, an Anti-EGFR Antibody with a Distinct Binding Epitope and Superior Inhibitory Activity against High-Affinity EGFR Ligands
2023 · Yangmi Lim, Jiho Yoo, et al.
Supplementary figure 2 from GC1118, an Anti-EGFR Antibody with a Distinct Binding Epitope and Superior Inhibitory Activity against High-Affinity EGFR Ligands
2023 · Yangmi Lim, Jiho Yoo, et al.
Supplementary table 2 from GC1118, an Anti-EGFR Antibody with a Distinct Binding Epitope and Superior Inhibitory Activity against High-Affinity EGFR Ligands
2023 · Yangmi Lim, Jiho Yoo, et al.
Supplementary figure 1 from GC1118, an Anti-EGFR Antibody with a Distinct Binding Epitope and Superior Inhibitory Activity against High-Affinity EGFR Ligands
2023 · Yangmi Lim, Jiho Yoo, et al.
Data from GC1118, an Anti-EGFR Antibody with a Distinct Binding Epitope and Superior Inhibitory Activity against High-Affinity EGFR Ligands
2023 · Yangmi Lim, Jiho Yoo, et al.
Works count: 26
Citation count: 34
H-index: 2
I10-index: 1
Year
Topic
Type